San Francisco, CA—Percutaneous closure of the patent ductus arteriosus (PDA) in children using a novel device is safe and effective, according to a prospective study presented in a featured clinical ...

New innovative capability brings lifesaving cardiac care directly to the NICU, reducing risks associated with transporting fragile premature infants. MIAMI , Sept. 22, 2025 /PRNewswire/ -- Nicklaus ...

“This position statement represents a collective effort between neonatology, anesthesia, and interventional cardiology to provide comprehensive guidance on tcPDA device occlusion that can be adapted ...

Abbott announced that the FDA approved a closure device for the treatment of premature babies with patent ductus arteriosus who are nonresponsive to medical management. The Amplatzer Piccolo occluder ...

The minimally invasive procedure involves placing a small catheter through a vein to deliver a tiny device that seals the PDA from within. The newly appointed chief of cardiovascular medicine and ...

MEMPHIS, Tenn. - Extremely low birth weight (ELBW) infants with moderate to large patent ductus arteriosus (PDA) may benefit from transcatheter PDA closure (TCPC) in the first four weeks of life, ...

Please provide your email address to receive an email when new articles are posted on . Compared with surgical ligation, transcatheter closure of the patent ductus arteriosus in infants and neonates ...

The Food and Drug Administration clearance and CE mark position Abbott to sell its Amplatzer Piccolo Delivery System in the U ...

Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer Piccolo™ Delivery System, which is used with the company's Amplatzer ...

Extremely low birth weight (ELBW) infants with moderate to large patent ductus arteriosus (PDA) may benefit from transcatheter PDA closure (TCPC) in the first four weeks of life, according to research ...